People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tricida, Inc. | — | Pharmaceuticals | Series C | $103.1M | $2.0B | 2013 |
Robert Alpern at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Alpern on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Hirsch | 1 | 16 |
| Klaus Veitinger | 1 | 6 |
| David Bonita | 1 | 6 |
| Gerrit Klaerner | 1 | 3 |
| Geoffrey Parker | 1 | 3 |
| Sandra Coufal | 1 | 3 |
| Melissa Miksch | 1 | 1 |
| Claire Lockey | 1 | 1 |
| Jerry Buysse | 1 | 1 |
| Edward Hejlek | 1 | 1 |
| Wilhelm Stahl | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.